Tuesday, June 29, 2021 2:00:35 PM
Dr. Williams will be speaking at the scientific conference at 11:30am ET on June 29, 2021.
The topic is “Personalized, off-the-shelf cellular immunotherapy for cancer”.
A copy of the presentation will be posted here: https://briacell.com/novel-technology/scientific-publications/.
For additional information on the conference and the speaker, please visit:
https://events.marketsandmarkets.com/4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition/speakers
Separately, BriaCell has recently appointed Miguel A. Lopez-Lago, Ph.D. as Senior Director, Research and Development. Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC). Specifically, he has investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis. More recently, Dr. Lopez-Lago has been interested in the study of the tumor immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor (CAR) T cell technologies. Since 2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his doctorate in Molecular Biology from Santiago of Compostela University, Spain.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
For additional information on BriaCell, please visit: https://briacell.com/.
Recent BCTX News
- BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients • GlobeNewswire Inc. • 09/18/2024 11:50:00 AM
- BriaCell Therapeutics Announces Closing of $8.5 Million Offering • GlobeNewswire Inc. • 09/12/2024 08:05:05 PM
- BriaCell Therapeutics Announces $8.5 Million Offering • GlobeNewswire Inc. • 09/11/2024 04:09:57 PM
- BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer • GlobeNewswire Inc. • 09/11/2024 11:50:00 AM
- BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer • GlobeNewswire Inc. • 09/10/2024 11:50:35 AM
- BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting • GlobeNewswire Inc. • 09/09/2024 11:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 08:30:28 PM
- BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer • GlobeNewswire Inc. • 07/18/2024 11:56:26 AM
- BriaCell Presents Clinical Efficacy Data at ASCO 2024 • GlobeNewswire Inc. • 06/03/2024 12:00:32 PM
- BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024 • GlobeNewswire Inc. • 05/24/2024 12:00:00 PM
- BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/17/2024 08:33:11 PM
- BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/15/2024 12:00:39 PM
- BriaCell Announces Oral and Poster Presentations at ASCO 2024 • GlobeNewswire Inc. • 04/24/2024 12:00:33 PM
- BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference • GlobeNewswire Inc. • 03/06/2024 01:00:26 PM
- BriaCell Provides Update on Alleged Illegal Trading of Public Securities • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case • GlobeNewswire Inc. • 02/07/2024 01:00:37 PM
- Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing • GlobeNewswire Inc. • 02/06/2024 01:30:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:24:58 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM